WO2020244657A1 - 抗b7-h4抗体-药物偶联物及其医药用途 - Google Patents
抗b7-h4抗体-药物偶联物及其医药用途 Download PDFInfo
- Publication number
- WO2020244657A1 WO2020244657A1 PCT/CN2020/094856 CN2020094856W WO2020244657A1 WO 2020244657 A1 WO2020244657 A1 WO 2020244657A1 CN 2020094856 W CN2020094856 W CN 2020094856W WO 2020244657 A1 WO2020244657 A1 WO 2020244657A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- drug conjugate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 158
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 158
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 150000003839 salts Chemical class 0.000 claims abstract description 112
- 239000002904 solvent Substances 0.000 claims abstract description 106
- 230000027455 binding Effects 0.000 claims abstract description 65
- 239000000427 antigen Substances 0.000 claims abstract description 59
- 108091007433 antigens Proteins 0.000 claims abstract description 59
- 102000036639 antigens Human genes 0.000 claims abstract description 59
- 239000012634 fragment Substances 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 120
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 34
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000001188 haloalkyl group Chemical group 0.000 claims description 26
- 241001529936 Murinae Species 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 102000055298 human VTCN1 Human genes 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- -1 chemotherapeutics Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 9
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 239000002254 cytotoxic agent Substances 0.000 claims description 9
- 210000004602 germ cell Anatomy 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 7
- 229910052805 deuterium Inorganic materials 0.000 claims description 7
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
- PTUJJIPXBJJLLV-UHFFFAOYSA-N 2-[[2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(=O)NC(C(=O)NCC(O)=O)CC1=CC=CC=C1 PTUJJIPXBJJLLV-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 229940122429 Tubulin inhibitor Drugs 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000001843 Carotid Body Tumor Diseases 0.000 claims description 2
- 208000037211 Carotid body tumour Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Chemical group 0.000 claims description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Chemical group 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Chemical group OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 2
- 206010073334 Rhabdoid tumour Diseases 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 208000025188 carcinoma of pharynx Diseases 0.000 claims description 2
- 230000032823 cell division Effects 0.000 claims description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 201000002529 islet cell tumor Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 235000018977 lysine Nutrition 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 230000001293 nucleolytic effect Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 2
- 208000010916 pituitary tumor Diseases 0.000 claims description 2
- 201000002267 posterior uveal melanoma Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011096 spinal cancer Diseases 0.000 claims description 2
- 208000014618 spinal cord cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 239000003744 tubulin modulator Substances 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000004474 valine Chemical group 0.000 claims description 2
- 235000014393 valine Nutrition 0.000 claims description 2
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 101710083262 Ectin Proteins 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 206010033964 Parathyroid tumour benign Diseases 0.000 claims 1
- 201000005476 astroblastoma Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 201000010103 fibrous dysplasia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 1
- 201000003686 parathyroid adenoma Diseases 0.000 claims 1
- 208000014643 parathyroid gland adenoma Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 27
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 230000002147 killing effect Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108010093470 monomethyl auristatin E Proteins 0.000 description 7
- 108010059074 monomethylauristatin F Proteins 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ADIJNQVLNHDJIF-UHFFFAOYSA-N S-(3-hydroxypropyl)-thioacetate Chemical compound CC(=O)SCCCO ADIJNQVLNHDJIF-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000981 bystander Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000013595 supernatant sample Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 0 CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1[C@@]([C@@](C)C(N[C@@](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)CIC(*)(*)*)=O)=O Chemical compound CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1[C@@]([C@@](C)C(N[C@@](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)CIC(*)(*)*)=O)=O 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012910 preclinical development Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008362 succinate buffer Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-L 2-(carboxylatomethoxy)acetate Chemical compound [O-]C(=O)COCC([O-])=O QEVGZEDELICMKH-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 238000011728 BALB/c nude (JAX™ mouse strain) Methods 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 208000008961 Fibrous Dysplasia of Bone Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 208000030224 brain astrocytoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 201000005252 lipomatous cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000013706 tumor of meninges Diseases 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Definitions
- B7-H4 protein is abundantly expressed in a variety of tumor tissues, allowing tumor cells to escape the body's immune system. Taking B7-H4 molecules as tumor therapy targets provides a new method for tumor immunotherapy.
- the purpose of the present invention is to provide an anti-B7-H4 antibody-drug conjugate, which has high affinity, high selectivity, high endocytic efficiency, high anti-cancer activity, and high stability Sex, high safety, low side effects, achieved through the following technical solutions:
- HCDR1 shown in SEQ ID NO: 3 HCDR2 shown in SEQ ID NO: 4, and HCDR3 shown in SEQ ID NO: 5;
- LCDR1, LCDR2, and LCDR as shown in SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34, respectively.
- LCDR1 shown in SEQ ID NO: 12 LCDR2 shown in SEQ ID NO: 13, and LCDR3 shown in SEQ ID NO: 14;
- LCDR1 shown in SEQ ID NO: 26 LCDR2 shown in SEQ ID NO: 27, and LCDR3 shown in SEQ ID NO: 28; or,
- LCDR1 shown in SEQ ID NO: 26 LCDR2 shown in SEQ ID NO: 27, and LCDR3 shown in SEQ ID NO: 28;
- the antibody-drug conjugate represented by general formula (A) or a pharmaceutically acceptable salt or solvent compound thereof as described above, wherein the Ab is a murine antibody or Fragments, chimeric antibodies or fragments thereof, human antibodies or fragments thereof, and humanized antibodies or fragments thereof.
- the heavy chain constant region includes a heavy chain constant region derived from human IgG1 or its variants, IgG2 or its variants, IgG3 or its variants or IgG4 or its variants, preferably derived from human IgG1, IgG2 or
- the heavy chain constant region of IgG4 more preferably the heavy chain constant region of IgG1 that enhances ADCC toxicity after amino acid mutation, most preferably the heavy chain constant region shown in SEQ ID NO: 54;
- the structure of MMAF and SN-38 is shown in the following formula:
- y is a number selected from 1 to 8, preferably a number selected from 2-4;
- n is an integer of 0-5, preferably 1, 2 or 3.
- the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvent compound thereof is an antibody-drug conjugate represented by general formula (IB) or Its pharmaceutically acceptable salt or solvent compound:
- mice can be immunized with human B7-H4 or fragments thereof, and the obtained antibodies can be renatured, purified, and amino acid sequencing can be performed by conventional methods.
- Antigen-binding fragments can also be prepared by conventional methods.
- the antibody or antigen-binding fragment of the invention is genetically engineered to add one or more human FR regions to the non-human CDR region.
- the human FR germline sequence can be obtained from the website http://imgt.cines.fr of ImmunoGeneTics (IMGT), or from the Journal of Immunoglobulin, 2001ISBN012441351.
- the heavy chain and light chain variable region sequences of mouse monoclonal antibody 2G6 are as follows:
- the Biacore method is a recognized method for objectively detecting the affinity and kinetics between proteins.
- the affinity and binding kinetics of the antibody to be tested of the present invention were analyzed by Biacore T200 (GE).
- the NHS standard amino coupling method is used to covalently connect the anti-B7-H4 antibody to be tested to the CM5 (GE) chip.
- 50nM human huB7-H4-His protein diluted in the same buffer was injected at a flow rate of 10uL/min. After injection, all were regenerated with the regeneration reagent in the kit. Track the antigen-antibody binding kinetics for 3 minutes and track the dissociation kinetics for 10 minutes.
- MX-1 cells are used for evaluation.
- MX-1 cells were trypsinized (washed with PBS first, 37°C, about 2min), collected and resuspended in pre-cooled FACS buffer, adjusting the cell concentration to 1 ⁇ 10 6 cells/mL.
- Take the EP tube add 1 mL of cell suspension, centrifuge at 1500 rpm for 5 minutes, and remove the supernatant. Add 1 mL of the prepared antibody to be tested to resuspend the cells. The final concentration of the antibody is 20 ⁇ g/ml.
- 2a (2g, 17.2mmol) was dissolved in 75mL of acetonitrile, and potassium carbonate (9.27g, 67.2mmol), benzyl bromide (20mL, 167.2mmol) and tetrabutylammonium iodide (620mg, 1.68mmol) were added in sequence.
- the reaction solution was stirred at room temperature for 48 hours, filtered through diatomaceous earth, the filter cake was rinsed with ethyl acetate (20ml), the combined filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography with a developing solvent system C to obtain Product 5a (3.2g, yield: 90.1%).
- reaction solution was purified by high performance liquid chromatography (separation conditions: column: XBridge Prep C18OBD 5um 19*250mm; mobile phase: A-water (10mmol NH 4 OAc): B-acetonitrile, gradient elution, flow rate: 18 mL/min ), the corresponding components were collected and concentrated under reduced pressure to obtain products 5-A and 5-B (3.6 mg, 2.6 mg).
- hu2F7-exitnotecan effectively killed NCI-H929-LUC cells, indicating that in the presence of B7-H4 positive cells, hu2F7-exitnotecan has a bystander killing effect, not only Kills B7-H4 positive cells, and can kill the originally insensitive B7-H4 negative cells (see “Single Cell Group”).
Abstract
Description
名称 | 序列 | 编号 |
HCDR1 | GFTFSRYGMS | SEQ ID NO:3 |
HCDR2 | GINGGGSYTYYLDTVKG | SEQ ID NO:4 |
HCDR3 | QGSNYYFDY | SEQ ID NO:5 |
LCDR1 | HASQGISSNIG | SEQ ID NO:6 |
LCDR2 | HGTNLED | SEQ ID NO:7 |
LCDR3 | VQYAQFPYT | SEQ ID NO:8 |
名称 | 序列 | 编号 |
HCDR1 | GFTFSNYYMS | SEQ ID NO:9 |
HCDR2 | YVSSGGGSTYYSDSVKG | SEQ ID NO:10 |
HCDR3 | ESYSQGNYFDY | SEQ ID NO:11 |
LCDR1 | RASQSISDYLH | SEQ ID NO:12 |
LCDR2 | FASQSIS | SEQ ID NO:13 |
LCDR3 | QNGHSFSLT | SEQ ID NO:14 |
名称 | 序列 | 编号 |
HCDR1 | GYTFTNSWMN | SEQ ID NO:23 |
HCDR2 | GIYPNSGNIEYNEKFKG | SEQ ID NO:24 |
HCDR3 | DSRFSY | SEQ ID NO:25 |
LCDR1 | KASQDVRTAVA | SEQ ID NO:26 |
LCDR2 | STSYRYT | SEQ ID NO:27 |
LCDR3 | QQHYSTPLT | SEQ ID NO:28 |
名称 | 序列 | 编号 |
HCDR1 | GDTFTTY | SEQ ID NO:29 |
HCDR2 | YLNSGS | SEQ ID NO:30 |
HCDR3 | DSRFSY | SEQ ID NO:31 |
LCDR1 | KASQDVSTAVA | SEQ ID NO:32 |
LCDR2 | SASYRYT | SEQ ID NO:33 |
LCDR3 | QQHYNTPLT | SEQ ID NO:34 |
抗体名称 | 与MX-1细胞的FACS Binding EC 50(nM) |
hu2G6 | 14.3 |
hu2F8 | 7.26 |
hu1C9 | 7.25 |
hu2F7 | 7.32 |
抗体 | 0小时(%) | 0.5小时(%) | 2小时(%) |
IgG对照 | 0 | 0.1 | 0.9 |
hu2G6 | 0 | 18.6 | 28.7 |
hu2F7 | 0 | 13.9 | 25.9 |
给药组 | 抑瘤率 |
hu2F7-MC-MMAF(y=2)3mg/kg | 87.99% |
hu2F7-MC-MMAF(y=4)3mg/kg | 197.87% |
Claims (41)
- 一种如通式(A)所示的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,Ab-(L 2-L 1-D) y(A)其中:D是细胞毒性药物;L 1、L 2是接头单元;y为1~20的数;Ab为B7-H4的抗体或其抗原结合片段,其包含抗体轻链可变区和抗体重链可变区,所述的抗体重链可变区包含至少1个选自如以下序列所示的HCDR:SEQ ID NO:3,SEQ ID NO:4,SEQ ID NO:5,SEQ ID NO:9,SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:23,SEQ ID NO:24,SEQ ID NO:25,SEQ ID NO:29,SEQ ID NO:30,SEQ ID NO:31,所述的抗体轻链可变区包含至少1个选自如以下序列所示的LCDR:SEQ ID NO:6,SEQ ID NO:7,SEQ ID NO:8,SEQ ID NO:12,SEQ ID NO:13,SEQ ID NO:14,SEQ ID NO:26,SEQ ID NO:27,SEQ ID NO:28,SEQ ID NO:32,SEQ ID NO:33,SEQ ID NO:34。
- 根据权利要求1所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab的抗体重链可变区包含选自以下(1)至(4)任一项的CDR:(1)SEQ ID NO:3所示的HCDR1、SEQ ID NO:4所示的HCDR2和SEQ ID NO:5所示的HCDR3;(2)SEQ ID NO:9所示的HCDR1、SEQ ID NO:10所示的HCDR2和SEQ ID NO:11所示的HCDR3;(3)SEQ ID NO:23所示的HCDR1、SEQ ID NO:24所示的HCDR2和SEQ ID NO:25所示的HCDR3;或,(4)SEQ ID NO:29所示的HCDR1、SEQ ID NO:30所示的HCDR2和SEQ ID NO:31所示的HCDR3。
- 根据权利要求1所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab的抗体轻链可变区包含选自以下(1)至(4)任一项的CDR:(1)SEQ ID NO:6所示的LCDR1、SEQ ID NO:7所示的LCDR2和SEQ ID NO:8所示的LCDR3;(2)SEQ ID NO:12所示的LCDR1、SEQ ID NO:13所示的LCDR2和SEQ ID NO:14所示的LCDR3;(3)SEQ ID NO:26所示的LCDR1、SEQ ID NO:27所示的LCDR2和SEQ ID NO:28所示的LCDR3;或,(4)SEQ ID NO:32所示的LCDR1、SEQ ID NO:33所示的LCDR2和SEQ ID NO:34所示的LCDR3。
- 根据权利要求1所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab的抗体重链可变区和抗体轻链可变区包含选自以下(1)至(4)任一项的CDR:(1)SEQ ID NO:3所示的HCDR1、SEQ ID NO:4所示的HCDR2和SEQ ID NO:5所示的HCDR3;以及SEQ ID NO:6所示的LCDR1、SEQ ID NO:7所示的LCDR2和SEQ ID NO:8所示的LCDR3;(2)SEQ ID NO:9所示的HCDR1、SEQ ID NO:10所示的HCDR2和SEQ ID NO:11所示的HCDR3;以及SEQ ID NO:12所示的LCDR1、SEQ ID NO:13所示的LCDR2和SEQ ID NO:14所示的LCDR3;(3)SEQ ID NO:23所示的HCDR1、SEQ ID NO:24所示的HCDR2和SEQ ID NO:25所示的HCDR3;以及SEQ ID NO:26所示的LCDR1、SEQ ID NO:27所示的LCDR2和SEQ ID NO:28所示的LCDR3;或,(4)SEQ ID NO:29所示的HCDR1、SEQ ID NO:30所示的HCDR2和SEQ ID NO:31所示的HCDR3;以及SEQ ID NO:32所示的LCDR1、SEQ ID NO:33所示的LCDR2和SEQ ID NO:34所示的LCDR3。
- 根据权利要求1-4中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab是鼠源抗体或其片段,嵌合抗体或其片段,人抗体或其片段以及人源化抗体或其片段。
- 根据权利要求1-5中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,所述Ab进一步包含(a)、(b)和(c)中的任一项或其组合:(a)源自人种系轻链和重链序列或其突变序列的轻链骨架区和重链骨架区;(b)源自人IgG1或其变体、IgG2或其变体、IgG3或其变体或IgG4或其变体的重链恒定区,优选源自人IgG1、IgG2或IgG4的重链恒定区,更优选氨基酸突变后增强ADCC毒性的IgG1的重链恒定区,最优选如SEQ ID NO:54所示的重链恒定区;(c)源自人κ链、λ链或其变体的轻链恒定区,优选源自人κ链的轻链恒定区,更优选如SEQ ID NO:55所示的轻链恒定区。
- 根据权利要求1-6中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab含有如下序列的轻链可变区:SEQ ID NO:16,SEQ ID NO:18,SEQ ID NO:36,SEQ ID NO:38,或与其具有至少70%,75%,80%,85%,90%,95%或99%同源性的轻链可变区。
- 根据权利要求1-7中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab含有如下序列的重链可变区:SEQ ID NO:15,SEQ ID NO:17,SEQ ID NO:35,SEQ ID NO:37,或与其具有至少70%,75%,80%,85%,90%,95%或99%同源性的重链可变区。
- 根据权利要求1-8中任一项所述的抗体-药物偶联物或其药学上可接受的 盐或溶剂化合物,其中所述Ab的轻链选自如下序列:SEQ ID NO:20,SEQ ID NO:22,SEQ ID NO:40,SEQ ID NO:42,或与其具有至少80%,85%,90%,95%或99%同源性的全长轻链。
- 根据权利要求1-9中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述的Ab的重链选自如下序列:SEQ ID NO:19,SEQ ID NO:21,SEQ ID NO:39,SEQ ID NO:41,或与其具有至少80%,85%,90%,95%或99%同源性的全长重链。
- 根据权利要求1-10中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab的重链可变区和轻链可变区选自以下任意一种:(1)SEQ ID NO:15所示的重链可变区和SEQ ID NO:16所示的轻链可变区;(2)SEQ ID NO:17所示的重链可变区和SEQ ID NO:18所示的轻链可变区;(3)SEQ ID NO:35所示的重链可变区和SEQ ID NO:36所示的轻链可变区;或,(4)SEQ ID NO:37所示的重链可变区和SEQ ID NO:38所示的轻链可变区。
- 根据权利要求11所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述Ab选自以下任意一种:(1)SEQ ID NO:20所示的轻链和如SEQ ID NO:19所示的重链;(2)SEQ ID NO:22所示的轻链和如SEQ ID NO:21所示的重链;(3)SEQ ID NO:40所示的轻链和如SEQ ID NO:39所示的重链;或,(4)SEQ ID NO:42所示的轻链和如SEQ ID NO:41所示的重链。
- 根据权利要求1-12中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述的抗原结合片段选自Fab、Fab'、F(ab')2、单链抗体、二聚化的V区、二硫键稳定化的V区和包含CDR的肽的抗原结合片段。
- 根据权利要求1-13中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述的细胞毒性药物选自毒素、化疗药物、抗生素、放射性同位素和核溶酶。
- 根据权利要求1-14中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述的细胞毒性药物选自抑制细胞分裂的微管蛋白抑制剂或DNA拓扑异构酶抑制剂;优选DM1、DM3、DM4、SN-38、MMAF或MMAE;更优选为微管蛋白抑制剂SN-38、MMAE或MMAF。
- 根据权利要求18-20中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,所述L 2如通式(D)所示:-K 1-K 2-K 3-K 4-(D)其中:K 2选自-NR 1(CH 2CH 2O) pCH 2CH 2C(O)-、-NR 1(CH 2CH 2O) pCH 2C(O)-、-S(CH 2) pC(O)-或单键,p为1至20的整数,优选1-6;R 1选自氢、氘、羟基、氨基、烷基、卤素、卤代烷基、氘代烷基和羟烷基;K 3为四肽残基,优选地,所述四肽残基由选自两个或多个的苯丙氨酸、甘氨酸、缬氨酸、赖氨酸、瓜氨酸、丝氨酸、谷氨酸、天冬氨酸中的氨基酸形成的肽残基;更优选为GGFG的四肽残基;K 4为-NR 2(CR 3R 4) t-,R 2、R 3或R 4各自独立地为氢、氘、羟基、氨基、烷基、卤素、卤代烷基、氘代烷基和羟烷基,t为1或2。
- 根据权利要求23所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述的接头单元-L 2-,其K 1端与Ab相连,K 4端与L 1相连。
- 根据权利要求18-20中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中:L 1选自-O-(CR aR b) m-CR 5R 6-C(O)-、-O-CR 5R 6-(CR aR b) m-、-O-CR 5R 6-、-NH-(CR aR b) m-CR 5R 6-C(O)-或-S-(CR aR b) m-CR 5R 6-C(O)-;R a和R b各自独立地选自氢、氘、卤素或烷基;R 5为卤代烷基或环烷基;R 6选自氢、卤代烷基或环烷基;或者,R 5和R 6与其相连接的碳原子一起形成环烷基;m为0、1、2、3或4。
- 根据权利要求25所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,其中L 1的O端与接头单元L 2相连。
- 根据权利要求1-12中任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物,所述抗体-药物偶联物如通式(IV)所示:其中:W选自C 1-8烷基、C 1-8烷基-环烷基或1至8个原子的直链杂烷基,所述杂烷基包含1至3个选自N、O或S的杂原子,其中所述的C 1-8烷基、环烷基和直链杂烷基任选地进一步被选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基的一个或多个取代基所取代;K 2选自-NR 1(CH 2CH 2O) p1CH 2CH 2C(O)-、-NR 1(CH 2CH 2O) p1CH 2C(O)-、-S(CH 2) p1C(O)-或键,R 1选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基,p 1 为1至20的整数;K 3为由2至7个氨基酸构成的肽残基,氨基酸可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基为一个或多个独立地选自卤素、羟基、氰基、氨基、烷基、氯代烷基、氘代烷基、烷氧基和环烷基;R 2独立地选自氢原子、烷基、卤代烷基、氘代烷基和羟烷基;R 3和R 4各自独立地选自氢原子、卤素、烷基、卤代烷基、氘代烷基和羟烷基;R 5选自卤素、卤代烷基、氘代烷基、环烷基、杂环基、芳基或杂芳基;R 6选自氢原子、卤素、卤代烷基、氘代烷基、环烷基、杂环基、芳基或杂芳基;或者,R 5和R 6与其相连接的碳原子一起形成环烷基或杂环基;m为0至4的整数;y为1至10,y是小数或整数;Ab为抗B7-H4抗体或其抗原结合片段。
- 一种药物组合物,其包含如权利要求1-35任一项所述的抗体-药物偶 联物或所述抗体-药物偶联物药学上可接受的盐或溶剂化合物,和一种或多种可药用的载体。
- 根据权利要求1-35任一项所述的抗体-药物偶联物或其药学上可接受的盐或溶剂化合物以及权利要求39所述的药物组合物在制备用于治疗与人B7-H4相关的疾病的药物中的应用。
- 根据权利要求40所述的应用,其特征在于,制备用于治疗B7-H4高表达癌症的药物中的应用,其中所述的癌症选自人脑星形胶质母细胞瘤、人咽头癌、肾上腺肿瘤、AIDS-相关癌症、腺泡状软组织肉瘤、星形细胞瘤、膀肮癌、骨癌、脑和脊髓癌、转移性脑瘤、乳腺癌、颈动脉体瘤、宫颈癌、软骨肉瘤、脊索瘤、肾嫌色细胞癌、透明细胞癌、结肠癌、结肠直肠癌、促结缔组织增生性小圆细胞肿瘤、室管膜细胞瘤、尤文肿瘤、骨外黏液样软骨肉瘤、骨纤维发育不全、骨纤维性发育不良、胆囊或胆管癌、胃癌、妊娠滋养细胞病、生殖细胞瘤、头颈癌、肝细胞癌、胰岛细胞瘤、卡波因肉瘤、肾癌、白血病、脂肪肉瘤/恶性脂肪瘤性肿瘤、肝癌、淋巴瘤、肺癌、成神经管细胞瘤、黑色素瘤、脑膜瘤、多发性内分泌瘤病、多发性骨髓瘤、骨髓增生异常综合征、成神经细胞瘤、神经内分泌肿瘤、卵巢癌、胰腺癌、乳头状甲状腺癌、甲状旁腺瘤、小儿癌症、外周神经鞘瘤、嗜铭细胞瘤、垂体肿瘤、前列腺癌、后葡萄膜黑色素瘤、肾转移性癌、横纹肌样瘤、横纹肌肉瘤、肉瘤、皮肤癌、软组织肉瘤、鳞状细胞癌、滑膜肉瘤、辜丸癌、胸腺癌、甲状腺转移性癌和子宫癌。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3142641A CA3142641A1 (en) | 2019-06-06 | 2020-06-08 | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
CN202080003353.0A CN112351797B (zh) | 2019-06-06 | 2020-06-08 | 抗b7-h4抗体-药物偶联物及其医药用途 |
EP20819019.9A EP3981434A4 (en) | 2019-06-06 | 2020-06-08 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND RELATED MEDICAL USE |
BR112021024406A BR112021024406A2 (pt) | 2019-06-06 | 2020-06-08 | Conjugado anticorpo-fármaco anti-b7-h4 e uso medicinal do mesmo |
AU2020288275A AU2020288275A1 (en) | 2019-06-06 | 2020-06-08 | Anti-B7-H4 antibody–drug conjugate and medicinal use thereof |
MX2021014960A MX2021014960A (es) | 2019-06-06 | 2020-06-08 | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. |
KR1020217043062A KR20220017946A (ko) | 2019-06-06 | 2020-06-08 | 항-b7-h4 항체-약물 접합체 및 이의 의학적 용도 |
US17/596,239 US20230072897A1 (en) | 2019-06-06 | 2020-06-08 | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
JP2021572039A JP2022535858A (ja) | 2019-06-06 | 2020-06-08 | 抗b7-h4抗体-薬物コンジュゲート及びその医薬的使用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910498993 | 2019-06-06 | ||
CN201910498993.2 | 2019-06-06 | ||
CN202010215322 | 2020-03-24 | ||
CN202010215322.3 | 2020-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020244657A1 true WO2020244657A1 (zh) | 2020-12-10 |
Family
ID=73652996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/094856 WO2020244657A1 (zh) | 2019-06-06 | 2020-06-08 | 抗b7-h4抗体-药物偶联物及其医药用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230072897A1 (zh) |
EP (1) | EP3981434A4 (zh) |
JP (1) | JP2022535858A (zh) |
KR (1) | KR20220017946A (zh) |
CN (1) | CN112351797B (zh) |
AU (1) | AU2020288275A1 (zh) |
BR (1) | BR112021024406A2 (zh) |
CA (1) | CA3142641A1 (zh) |
MX (1) | MX2021014960A (zh) |
TW (1) | TW202112398A (zh) |
WO (1) | WO2020244657A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021115426A1 (zh) * | 2019-12-12 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | 抗密蛋白抗体药物偶联物及其医药用途 |
WO2021249228A1 (zh) | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物 |
WO2022056696A1 (zh) * | 2020-09-15 | 2022-03-24 | 四川百利药业有限责任公司 | 一种喜树碱类药物及其抗体偶联物 |
CN114409562A (zh) * | 2021-02-08 | 2022-04-29 | 四川百利药业有限责任公司 | 一种ca4衍生物及其配体-药物偶联物 |
WO2022161385A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海翰森生物医药科技有限公司 | 一种抗体药物偶联物及其医药用途 |
WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
WO2022228406A1 (zh) * | 2021-04-26 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途 |
WO2023178641A1 (zh) | 2022-03-25 | 2023-09-28 | 成都百利多特生物药业有限责任公司 | 一种dna毒性二聚体化合物及其偶联物 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
US11964024B2 (en) | 2021-01-04 | 2024-04-23 | Mersana Therapeutics, Inc. | B7H4-targeted antibody-drug conjugates and methods of use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022511351A (ja) * | 2018-09-26 | 2022-01-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 実験動物のリガンド-薬剤共役、その調製方法およびその適用 |
CN113816969B (zh) * | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
TW202340255A (zh) * | 2022-03-30 | 2023-10-16 | 大陸商映恩生物製藥(蘇州)有限公司 | B7h4抗體藥物偶聯物及其用途 |
KR20240001074A (ko) * | 2022-06-24 | 2024-01-03 | 주식회사 피노바이오 | 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물접합체 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005081711A2 (en) | 2003-11-06 | 2005-09-09 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
CN101951959A (zh) * | 2007-11-30 | 2011-01-19 | 百时美施贵宝公司 | 抗b7h4单克隆抗体-药物缀合物和使用方法 |
WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
CN103561772A (zh) * | 2011-05-26 | 2014-02-05 | 百时美施贵宝公司 | 免疫缀合物、含有免疫缀合物的组合物及制备方法和用途 |
US20140322129A1 (en) | 2013-03-14 | 2014-10-30 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
CN105189552A (zh) * | 2013-03-14 | 2015-12-23 | 基因泰克公司 | 抗b7-h4抗体和免疫缀合物 |
US20180021270A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
WO2018065501A1 (en) * | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
WO2019154315A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6943760B2 (ja) * | 2014-09-12 | 2021-10-06 | ジェネンテック, インコーポレイテッド | 抗b7−h4抗体及び免疫複合体 |
-
2020
- 2020-06-08 EP EP20819019.9A patent/EP3981434A4/en active Pending
- 2020-06-08 CA CA3142641A patent/CA3142641A1/en active Pending
- 2020-06-08 TW TW109119191A patent/TW202112398A/zh unknown
- 2020-06-08 KR KR1020217043062A patent/KR20220017946A/ko unknown
- 2020-06-08 MX MX2021014960A patent/MX2021014960A/es unknown
- 2020-06-08 AU AU2020288275A patent/AU2020288275A1/en active Pending
- 2020-06-08 BR BR112021024406A patent/BR112021024406A2/pt unknown
- 2020-06-08 CN CN202080003353.0A patent/CN112351797B/zh active Active
- 2020-06-08 JP JP2021572039A patent/JP2022535858A/ja active Pending
- 2020-06-08 US US17/596,239 patent/US20230072897A1/en active Pending
- 2020-06-08 WO PCT/CN2020/094856 patent/WO2020244657A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005081711A2 (en) | 2003-11-06 | 2005-09-09 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
CN101951959A (zh) * | 2007-11-30 | 2011-01-19 | 百时美施贵宝公司 | 抗b7h4单克隆抗体-药物缀合物和使用方法 |
CN103561772A (zh) * | 2011-05-26 | 2014-02-05 | 百时美施贵宝公司 | 免疫缀合物、含有免疫缀合物的组合物及制备方法和用途 |
WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
US20140322129A1 (en) | 2013-03-14 | 2014-10-30 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
CN105189552A (zh) * | 2013-03-14 | 2015-12-23 | 基因泰克公司 | 抗b7-h4抗体和免疫缀合物 |
US20180021270A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
WO2018065501A1 (en) * | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
WO2019154315A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
Non-Patent Citations (9)
Title |
---|
CHOI IH ET AL., J IMMUNOL., vol. 171, no. 9, 1 November 2003 (2003-11-01), pages 4650 - 4 |
HOLLIGERHUDSON, NAT. BIOTECHNOL., vol. 23, 2005, pages 1126 - 1136 |
J. BIOL. CHEM, vol. 243, 1968, pages 3558 |
KRYCZEK, I ET AL., J. EXP. MED., vol. 203, no. 4, 2006, pages 871 - 881 |
LEONG STEVEN R; LIANG WEI-CHING; WU YAN; CROCKER LISA; CHENG ERIC; SAMPATH DEEPAK; OHRI RACHANA; RAAB HELGA; HASS PHILIP E; PHAM T: "An Anti-B7-H4 Antibody-Drug Conjugate for the Treatment of Breast Cancer", MOLECULAR PHARMACEUTICS, vol. 12, no. 6, 23 April 2015 (2015-04-23) - 1 June 2015 (2015-06-01), pages 1717 - 1729, XP008178294 * |
See also references of EP3981434A4 |
SICA GL ET AL., IMMUNITY, vol. 18, no. 6, June 2003 (2003-06-01), pages 849 - 61 |
SUH WK ET AL., BLOOD. MOL CELL BIOL., vol. 26, no. 17, pages 6403 - 11 |
ZHU G ET AL., BLOOD, vol. 113, no. 8, 19 February 2009 (2009-02-19), pages 1759 - 67 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021115426A1 (zh) * | 2019-12-12 | 2021-06-17 | 江苏恒瑞医药股份有限公司 | 抗密蛋白抗体药物偶联物及其医药用途 |
WO2021249228A1 (zh) | 2020-06-08 | 2021-12-16 | 四川百利药业有限责任公司 | 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物 |
WO2022056696A1 (zh) * | 2020-09-15 | 2022-03-24 | 四川百利药业有限责任公司 | 一种喜树碱类药物及其抗体偶联物 |
US11964024B2 (en) | 2021-01-04 | 2024-04-23 | Mersana Therapeutics, Inc. | B7H4-targeted antibody-drug conjugates and methods of use thereof |
WO2022161385A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海翰森生物医药科技有限公司 | 一种抗体药物偶联物及其医药用途 |
CN114409562A (zh) * | 2021-02-08 | 2022-04-29 | 四川百利药业有限责任公司 | 一种ca4衍生物及其配体-药物偶联物 |
WO2022166719A1 (zh) * | 2021-02-08 | 2022-08-11 | 四川百利药业有限责任公司 | 一种ca4衍生物及其配体-药物偶联物 |
WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
WO2022228406A1 (zh) * | 2021-04-26 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023178641A1 (zh) | 2022-03-25 | 2023-09-28 | 成都百利多特生物药业有限责任公司 | 一种dna毒性二聚体化合物及其偶联物 |
Also Published As
Publication number | Publication date |
---|---|
EP3981434A4 (en) | 2023-11-01 |
EP3981434A1 (en) | 2022-04-13 |
US20230072897A1 (en) | 2023-03-09 |
KR20220017946A (ko) | 2022-02-14 |
AU2020288275A1 (en) | 2022-02-03 |
BR112021024406A2 (pt) | 2022-04-19 |
CA3142641A1 (en) | 2020-12-10 |
CN112351797B (zh) | 2023-12-22 |
MX2021014960A (es) | 2022-03-04 |
JP2022535858A (ja) | 2022-08-10 |
TW202112398A (zh) | 2021-04-01 |
CN112351797A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020244657A1 (zh) | 抗b7-h4抗体-药物偶联物及其医药用途 | |
CN112543771B (zh) | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 | |
JP2024026132A (ja) | 抗b7-h4抗体、その抗原結合断片及びその医薬用途 | |
WO2021190586A1 (zh) | B7h3抗体-依喜替康类似物偶联物及其医药用途 | |
WO2021190480A1 (zh) | 抗体-药物偶联物及其医药用途 | |
WO2021190564A1 (zh) | 抗体药物偶联物及其医药用途 | |
CN112585168B (zh) | 抗bcma抗体、其抗原结合片段及其医药用途 | |
JP2023506805A (ja) | 抗cea抗体-エキサテカン類似体複合体及びその医薬用途 | |
TWI839556B (zh) | 抗bcma抗體、其抗原結合片段及其醫藥用途 | |
WO2023046003A1 (zh) | 抗体药物偶联物及其制备方法和医药用途 | |
RU2785664C2 (ru) | Конъюгат антитело к b7h3-аналог экзатекана и его применение в медицине | |
WO2022161385A1 (zh) | 一种抗体药物偶联物及其医药用途 | |
KR20240058146A (ko) | 항체-약물 접합체, 이의 제조 방법 및 의약적 용도 | |
CN115998900A (zh) | 抗trop-2抗体药物偶联物及其医药用途 | |
WO2023245021A2 (en) | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof | |
CN117425500A (zh) | 抗dll3抗体-药物缀合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20819019 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021572039 Country of ref document: JP Kind code of ref document: A Ref document number: 3142641 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021024406 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20217043062 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020819019 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112021024406 Country of ref document: BR Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DAS PRIORIDADES CN 201910498993.2 DE 06/06/2019 E CN 202010215322.3 DE 24/03/2020 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO. |
|
ENP | Entry into the national phase |
Ref document number: 2020288275 Country of ref document: AU Date of ref document: 20200608 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021024406 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211202 |